 |
|
|
| |
Safety and Efficacy of Switching From Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in People With HIV Aged 50 Years and Older
|
| |
| |
17th European AIDS Conference (EACS), 6-9 November 2019, Basel, Switzerland
Reported by Jules Levin
Hans-Jurgen Stellbrink,1 Frank A. Post,2 Daniel Podzamczer,3 Jose Arribas,4 Eric Cua,5 Jean-Michel Molina,6 Chloe Orkin,7 Jurgen K. Rockstroh,8 Christoph Carter,9 Ya-Pei Liu,9 Lijie Zhong,9 Moupali Das,9 Lauren Temme,9 Laura Waters10
1ICH Study Center, Hamburg, Germany; 2King's College Hospital, London, UK; 3Hospital Universitari de Bellvitge, Barcelona, Spain; 4Hospital Universitario La Paz, Madrid, Spain; 5Hopital L'Archet, Nice, France; 6Hopital Saint-Louis, Paris, France; 7Barts Health NHS Trust, London; 8Universitätsklinikums Bonn, Germany; 9Gilead Sciences, Inc., Foster City, California, USA; 10Mortimer Market Centre, London
References: 1. Autenrieth CS, et al. PLoS One. 2018;13:e0207005; 2. Tavoschi L, et al. Lancet HIV. 2017;4:e514-21; 3. Ruane PJ, et al. J Acquir Immune Defic Syndr 2013;63:449-55; 4. Arribas J, et al. J Acquir Immune Defic Syndr 2017;75:211-8; 5. Gupta SK, et al. AIDS 2019;33:1455-65; 6. Sax P, et al. J Acquir Immune Defic Syndr 2014;67:52-8; 7. Glidden D, et al. Clin Infect Dis 2018;67:411-9; 8. Tungsiripat M, et al. AIDS 2010;24:1781-4. Acknowledgments: We extend our thanks to the participants and their families. These studies were funded by Gilead Sciences, Inc.
|
| |
|
|
|
|
|
